Ficerafusp Alfa (BCA101) With Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Two-Year Results of an Expansion Cohort of a Phase I/Ib Trial.

Journal:

Journal of Clinical Oncology

Published:

2026-05-09

DOI:

10.1200/jco-25-02027

Affiliations:

10

Authors:

15

Go to article

Institutions	Authors	Share
Bicara Therapeutics, United States of America (USA)	6.000000	0.40
Moores Cancer Center, United States of America (USA)	1.000000	0.07
UPMC Hillman Cancer Center (UPCI), United States of America (USA)	1.000000	0.07
Hollings Cancer Center, MUSC, United States of America (USA)	1.000000	0.07
H. Lee Moffitt Cancer Center & Research Institute, United States of America (USA)	1.000000	0.07
Memorial Sloan Kettering Cancer Center (MSKCC), United States of America (USA)	1.000000	0.07
Dana-Farber Cancer Institute (DFCI), United States of America (USA)	1.000000	0.07
Ronald Reagan UCLA Medical Center, United States of America (USA)	1.000000	0.07
Princess Margaret Cancer Centre, U of T, Canada	1.000000	0.07
Cleveland Clinic, United States of America (USA)	1.000000	0.07

Interested in Oncology and Carcinogenesis?